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Abstract
During the past 10 years we have experienced very significant
developments in our understanding of bone biology, and this has
improved our abilities to both diagnose and treat patients with
osteoporosis. This review covers some of the significant
discoveries in bone biology that have led to a better understanding
of osteoporosis, including a few of the discoveries that have been
translated into new therapies to treat patients with osteoporosis
and the structural deterioration of patients with inflammatory
arthritis.
Introduction
Bone is a mineralized tissue that has recognized mechanical
functions, including protection and support for the internal
organs and for locomotion. Bone tissue is constantly ‘turning
over’, allowing bone to repair itself, for instance after a
fracture, and to adapt to the mechanical loads that are placed
on it. In the adult skeleton, the rate of bone turnover, collagen
matrix, structure, geometry, and density all combine to
determine the bone’s overall mechanical competence.
Defects in these parameters can result in diseases such as
osteoporosis, osteopetrosis, osteogenesis imperfecta, and
Paget’s disease [1,2].
The dynamic nature of the skeleton is achieved by a process
of bone remodeling. Bone is continuously replaced during
adult life through tightly coupled bone resorption by osteo-
clasts and bone formation by osteoblasts, as well as
osteocytes within the bone matrix and bone lining cells that
cover the bone surface. The coordinated action of these cells
is described as the ‘basic multicellular unit’ (BMU). Within the
BMU cellular activity is coupled; in principle the amount of
bone that is removed is replaced. The remodeling cycle
occurs continuously at discrete sites throughout the skeleton
in response to mechanical and metabolic influences.
Remodeling starts with the initiation of osteoclast formation,
osteoclast-mediated bone resorption, and a reversal period.
Then there is a longer period of bone formation mediated by
osteoblasts, followed by the full mineralization of the newly
formed bone matrix [1-3]. There is now evidence to support
that these bone cells communicate with each other and
osteocytes embedded in the mineralized matrix. Apart from
BMU cells, T lymphocytes, B lymphocytes, and neural cells
also communicate with the bone cells [4-6]. This review is
limited to the advances that have been made in our under-
standing of bone biology and will include the differentiation
and local regulation of bone cells.
Osteoblasts
Our understanding of osteoblast differentiation and local
regulation has increased over the past 10 years through the
discovery of the canonical Wnt signaling pathway. The Wnt
family of glycoproteins represents a major signaling pathway
that is involved in cellular differentiation. Secreted Wnt
proteins act on target cells by binding to the frizzled and low-
density lipoprotein receptor-related protein (LRP) complex on
the cell surface. The binding signal is transduced to
intracellular proteins including dishelved, glycogen synthase
kinase-3, axin, adenomatous polyposis coli, and β-catenin,
which functions as a transcriptional regulator [7]. If Wnt
proteins are not present, then glycogen synthase kinase-3
constitutively phosphorylates the β-catenin protein, which
leads to degradation and this provides a mechanism to
maintain a low concentration of β-catenin in the cytoplasm of
the cell. The binding of Wnt proteins act on the target cell by
binding to frizzled receptors and their co-receptor LRP5/6
that stabilizes cytoplasmic β-catenin protein, which in turn
translocates to the nucleus and activates the transcription of
target genes via transcription factors including lymphoid
enhancer-binding factor and T-cell factors [8,9]. There are
also antagonists of the Wnt signaling pathway, which include
secreted frizzled-related protein (SFRP)1, Wnt inhibitory
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factor (WIF)-1, dickkopf (DKK)-1, and sclerostin; these either
bind to LRP5/6 or inactive LRP5/6, such that the Wnt
signaling is stopped.
The Wnt signaling pathway is well known in developmental
biology and growth, and metastases of cancer, but the
connection to the skeleton was not initially clear [10,11].
However, a family was described that had a loss of function
of Lrp5, which was known to be a co-receptor in the Wnt
signaling pathway, members of which had low bone density
(osteoporosis pseudoglyoma syndrome); another family was
described with a gain of function of Lrp5, resulting in a high
bone mass phenotype [12-14]. These clinical observations
have been confirmed in studies in which mice were
generated that exhibited either no Lrp5 function or increased
Lrp5 function; bone mass findings were similar [12-18]. Also,
mutations in the gene encoding sclerostin (Sost), an
antagonist of Wnt signaling, resulted in a high bone mass
disease (van Buchem disease or sclerostosis syndrome)
[19-22]. Over-expression of DKK-1 induces osteopenia in
mice [23], whereas deletion of a single allele of the DKK-1
gene leads to an increase in bone formation and bone mass
[24]. Increased production of DKK-1 by plasmacytoid cells in
patients with multiple myeloma are responsible for the
osteocytic lesions observed in that disease [25,26]. Also, in
patients with prostate and breast cancer bone metastasis,
DKK-1 production has been reported to be responsible for
development of osteolytic bone lesions in these diseases
[27,28].
The pathogenesis of glucocorticoid-induced osteoporosis
may also involve increased expression of DKK-1, which
suppresses osteoblastic differentiation through the Wnt
pathway [29]. We conducted a microarray on whole bone
extracts from mice that were treated with glucocorticoids for
56 days and found that Wnt antagonists - including DKK-1,
sclerostin, and WIF-1 - were upregulated from days 28 to 56
[30]. Thus, suppression of Wnt signaling may be responsible
for part of the pathogenesis of prolonged suppression of
bone formation after glucocorticoid administration. Concur-
rent treatment of glucocorticoid-treated mice with parathyroid
hormone (PTH) for 28 days reversed the elevation of DKK-1
and was associated with increased osteogenesis.
Secreted frizzled related protein-1 and bone
formation
SFRP1 is a soluble inhibitor of Wnt signaling. Its role in bone
formation is now just being discovered. Adult mice deficient
in  sFRP1 exhibited increased trabecular bone accrual and
resistance to age-related bone loss. Mice with over-expres-
sion of sFRP1 (sFRP1-transgenic mice) exhibited osteopenia
with lower osteoblastogenesis and bone formation, with
males being more severely affected than females [31]. The
reduced bone mass in sFRP1-transgenic mice was accom-
panied by evidence of reduced osteogenesis, with reduced
alkaline phosphatase and mineralized nodule formation in
vitro. In vitro osteoclastogenesis was also higher in sFRP1-
transgenic mice. sFRP1-transgenic mice treated for 2 weeks
with high-dose human PTH(1-34) (hPTH[1-34]) exhibited
almost no increase in bone mass compared with wild-type
mice [31]. SFRP1 over-expression appears to counteract the
PTH-induced increases in osteoblast differentiation and
activity. Expression levels of osteogenic genes (RUNX2 and
the genes encoding osterix and osteocalcin) were lower in
sFRP1-transgenic mice treated with PTH, as compared with
levels in wild-type mice. These data suggest that this Wnt
signaling inhibitor not only reduced osteogenesis but also
appeared to augment osteoclastogenesis, possibly through
increased production of receptor activator of nuclear factor-
κB ligand (RANKL) by pre-osteoblasts and reduced produc-
tion of osteoprotegerin (OPG) by mature osteoblasts.
New studies that may expand our
understanding of the Wnt signaling pathway
and bone formation
The discovery of mutations in the Wnt pathway - specifically
mutations in LRP5, which is the co-receptor for Wnt proteins
and is associated with a phenotype of low bone mass, namely
osteoporosis pseudoglioma syndrome (OPPG) - led to the
view that canonical Wnt signaling through the cell surface
receptor LRP5 or LRP6 controlled osteoblast formation or
action. Osteogenesis is stimulated by canonical Wnt
signaling in a number of ways (Figure 1). In the early stages of
differentiation of mesenchymal stem cells to osteoblast
precursors, Wnt signaling agonists direct these precursor
cells toward osteogenesis and prevent the alternative
differentiation of these stem cells toward adipocytes and
chondrocytes [32,33] through translocation of β-catenin to
the nucleus and activation of transcription of genes involved
in osteogenesis [34-36]. Findings in Lrp5 knockout mice
support a further role for Wnt signaling in osteoblast function,
because these mice exhibited reduced bone matrix
deposition [37]. Over-expression of β-catenin can result in
increased collagen production [38]. Also, another osteogenic
effect of Wnt signaling, namely that it reduced apoptosis of
osteoblasts and osteocytes, has been reported [35].
Despite the strong evidence to support the role played by
LRP5 or LRP6 in bone formation, the evidence to support
canonical Wnt signaling in osteoblasts was less clear. Mice
null for Lrp5 did have low bone mass, which is similar to the
clinical phenotype of OPPG. However, in mice null for β-
catenin, mature osteoblasts had a normal phenotype but
exhibited increased osteoclastogenesis, which did not
support a role for β-catenin in osteogenesis [37]. This led to
the hypothesis that LRP5 may control bone formation inde-
pendent of Wnt/β-catenin signaling.
Investigators conducted microarray analyses of bone and
other organ tissues from Lrp5 knockout mice and found that
the gene encoding tryptophan hydroxylase (Tph1), a rate-
limiting enzyme involved in serotonin synthesis, was highlyexpressed in the enterochromaffin cells of the duodenum, and
serum serotonin levels were high compared with those in
wild-type control animals [11]. The investigators went on to
demonstrate that LRP5 augmentation of bone formation and
accrual of bone mass appeared to be through the inhibition of
Tph1 expression and serotonin synthesis in enterochromaffin
cells in the duodenum. Serotonin appears to inhibit osteo-
blast proliferation by binding to its receptor, 5-hydroxy-
tryptamine receptor 1B, on the osteoblast surface [31]. The
investigators further demonstrated that the animals with
mutations in Lrp5 (OPPG) have high circulating serotonin
levels [11]. A number of studies have reported that patients
receiving serotonin re-uptake inhibitors have low bone mass
compared with age-matched control individuals, suggesting
that if circulating levels of serotonin are increased in these
patients then they may have reduced bone formation [39,40].
Although more work is needed in this area, these experiments
have increased our understanding of how LRP5 may work to
increase osteoblast proliferation, and provide new data to
support a mechanism by which intestine and bone may
communicate. A few years ago, the discovery of LRP5 as a
disease with a clinical phenotype of low bone mass was the
beginning of the research directed at elucidating how the
Wnt signaling pathway regulates bone formation. However,
this new work by Yadav and coworkers [11] suggests that
the influence of Wnt/LRP5 may be indirect and may partially
work through the intestine.
Osteocytes: key regulators of the skeletal
response to mechanical loading and bone
formation
Over the past 10 years, our scientific understanding of
osteocytes and their role in bone metabolism has significantly
increased. The osteocyte, which is the most abundant cell
type in bone, resides in the lacuna/canalicular system, and
strong evidence supports its role in the control of local bone
remodeling. These cells are nonproliferative terminally
differentiated cells of the osteoblast lineage [41]. They form
an extensive network of canaliculi that connect these cells to
each other, blood vessels, and the bone surface. The surface
area of the lacuna/canalicular system is large - more than 100
times that of the trabecular bone surface [41]. The canalicular
system of communication for the osteocytes is similar to that
of the nervous system, in that there are a large number of low
activity cells connected through the canaliculi, and it is
hypothesized to be an efficient way to transmit signals over
long distances [42]. The osteocytes are also surrounded
within their lacunae by proteoglycans, which are
hypothesized to assist in the amplification of fluid flow-derived
mechanical signals. Each osteocyte has a cilium that extends
from its cell cytoplasm, which may also translate the fluid flow
signal to the osteocyte [41].
It has long been known that mechanical stress induced by
weight-bearing exercise increases osteoblast activity.
However, the absence of mechanical stimulation resulting
from immobilization or bed rest can cause rapid bone loss
[41]. Based on these findings, it has been postulated that
osteocytes are mechano-sensitive cells and that the lacunae/
canaliculi carry the signaling molecules that are responsible
for maintenance of bone structure and mass [41,43]. The
model has been proposed to explain how mechanical loading
can induce the biochemical transmission that promotes bone
formation and remodeling.
During the 1960s a phenomenon was reported that was
referred to as ‘osteocytic osteolysis’, in which large osteocyte
lacunae were observed within the cortex and the trabeculae,
in patients with hypophosphotemic rickets [44-47]. This
observation that the osteocyte can modify its micro-
environment was not confirmed by other laboratories and was
not validated until very recently. Our laboratory group studied
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Figure 1
Pathways for osteogenesis and osteoclastogenesis. Osteoblasts
mature from mesenchymal stem cells to preosteoblasts. The Wnt
signaling pathway antagonists (DKK-1, sclerostin, and SFRP1) and
serotonin all inhibit osteogenesis. A number of cell types can
synthesize Wnt signaling antagonists. Fibroblast-like synoviocytes from
rheumatoid arthritis patients after stimulation with TNF-α, and myeloma
cells synthesize DKK-1 and osteocytes synthesize sclerostin.
Osteoblasts also now are known to be the main controllers of
osteoclastogenesis through the production of RANKL by pre-
osteoblast cells. The antagonist of RANKL, OPG, is produced by
mature osteoblasts and prevents RANKL from binding to its receptor,
RANK, so that osteoclast maturation and activity are inhibited. DKK,
dickkopf; OPG, osteoprotegerin; RANKL, receptor activator of nuclear
factor-κB ligand; SFRP, secreted frizzled-related protein; TNF, tumor
necrosis factor.a mouse model of glucocorticoid-induced bone loss and
reported some novel observations about osteocytes
[30,48,49]. Glucocorticoid treatment initially increased
osteoclast maturation and activity, and this was followed by
delayed but prolonged suppression of bone formation.
Trabecular bone loss with glucocorticoid treatment was
about 20% over 21 days. Analysis of gene expression from
the bone revealed elevation of osteoclastogenic genes for the
first 7 days of glucocorticoid treatment, followed by suppres-
sion of osteogenic genes, and an increase in dentin matrix
protein-1, sclerostin, and other Wnt signaling inhibitors (DKK-
1 and WIF). Interestingly, atomic force microscopy and raman
microscopy of the trabecular surface from the individual
trabeculae in glucocorticoid-treated mice demonstrated
enlarged osteocyte lacunae and areas of low elastic modulus
and low bone mineral [30,48,49]. These findings suggested
that glucocorticoid treatment was associated with changes in
both bone remodeling and osteocyte metabolism, which may
result in localized changes in bone strength at the bone
surface and within bone tissue; this may begin to explain the
increased bone fragility in patients receiving glucocorticoids.
That the osteocyte can modify its microenvironment and
enlarge the lacunae has been observed in the settings of
prolonged estrogen deficiency in rats, hypophosphatemic
rickets in mice, and lactating mice [41-43]. However, we are
not yet able to determine the stimuli that are responsible for
the osteocyte’s action. Currently, the three clinical conditions
associated with enlarged osteocyte lacunae - namely hypo-
phosphotemic rickets, lactation in mice, and glucocorticoids
in mice - suggest that the lacunae may enlarge and contract
depending on the need to mobilize calcium from the skeleton.
Estimates of surface-based bone remodeling indicate that the
number of osteoclasts that can occupy the bone surface is
insufficient to maintain calcium balance in most rodents and
animals. It is possible that the osteocyte, under certain
physiologic conditions, can participate in mobilizing calcium
from the skeleton to maintain calcium balance [50].
The functional role of the osteocyte in bone
The recent discovery of sclerostin is an example of an
osteocyte-derived signal that can inhibit bone formation.
Sclerostin is a Wnt signaling antagonist and is known to
inhibit osteogenesis [41,51]. Sclerostin gene expression has
been reported to be responsive to mechanical stimulation,
PTH treatment, and glucocorticoid treatment [49,52,53].
Recent work has shown that when osteocytes produce
sclerostin, it moves through the canaliculi into the bone
marrow and appears to reduce osteoblast differentiation and
bone formation through its inhibition of frizzled/LRP5/6
transmembrane signaling. Treatment with hPTH(1-34), an
anabolic agent that stimulates bone formation, has been
found to reduce sclerostin expression in osteocytes in animal
models [43,49,52,53]. Although rare, clinically observed
diseases of sclerostin production - sclerosteosis and Van
Buchem disease - are high bone mass disorders that have
been linked to deficiencies in the SOST gene (which
encodes sclerostin). Mice that are null for sclerostin have very
high bone mass phenotypes [54], and treatment of osteo-
penic mice with anti-sclerostin antibody restored bone mass
compared with that in control animals [55].
Because sclerostin is produced in adults, primarily in
osteocytes, and appears to inhibit bone formation through
inhibition of Wnt signaling, this aspect of osteocyte biology
may be very important for the development of an anabolic
agent to treat osteoporosis. In a phase I clinical study in
postmenopausal women treated with a number of doses of a
sclerostin antibody, it was found that 85 days after the study
subjects received the anti-sclerostin antibody, they had a
dose-related increase of 60% to 100% in bone formation
markers amino-terminal propeptide of type I procollagen
(P1NP) and bonespecific alkaline phosphatase (BSAP), and
a trend toward a dose-related decrease in a serum marker of
bone resorption, namely C-telopeptide crosslink of type I
collagen (CTX) [56]. Currently, phase II clinical trials with a
monoclonal antibody directed against sclerostin are
underway. This therapy, directed at the inhibition of
osteocyte-derived sclerostin, may be a potential new anabolic
therapy for patients with osteoporosis.
Recent developments in our understanding of
osteoclastogenesis
Our understanding of the activation process in osteoclasts
represents one of the most important discoveries in bone
biology over the past 10 years. In summary, the activator of
resorption, known as RANKL, is expressed by osteoblasts
and binds to its receptor RANK on osteoclasts [57-59].
RANKL is a member of the tumor necrosis family, and it is the
most important of the cytokines involved in the final stages of
osteoclast maturation and activity.
Osteoclasts are derived from precursor cells belonging to the
monocyte/macrophage lineage from bone marrow. In vitro
studies have found that RANKL is expressed on immature
osteoblasts in the presence of macrophage colony stimu-
lating factor, activates RANK, induces the formation of
osteoclasts through recruitment of osteoclast precursors in
the marrow, and promotes their differentiation and fusion into
multinucleated osteoclasts, which are responsible for
resorption. Several cytokines are involved in the events that
also promote osteoclast development, including macrophage
colony-stimulating factor, which is essential for RANKL’s
action in osteoclastogenesis; IL-1, which is derived from
osteoblasts and is a potent stimulator of RANKL; and IL-6,
which is produced by osteoclasts in response to PTH and
1,25-dihydroxyvitamin D. T lymphocytes that produce IL-15
and IL-17 are also reported to support osteoclastogenesis.
Although there are a number of systemic factors that initiate
osteoclastogenesis, they all appear to work via the final
common pathway of increasing production of RANKL by
osteoblasts [59].
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soluble receptor OPG, which is secreted by osteoblasts, and
stromal cells, which belong to the tumor necrosis factor
(TNF) receptor family [59,60]. The actions of RANKL and
OPG on osteoclastogenesis were demonstrated in a number
of experiments in mice. Mice over-expressing OPG had high
bone mass and those without OPG had very low bone mass
[61]. Treatment of estrogen-deficient mice with a monoclonal
antibody to OPG prevented bone loss [59,60], and mice
without RANKL had high bone mass [62]. These important
studies demonstrated that the RANKL/RANK/OPG system is
a key regulator of osteoclast maturation and activity [59].
The preclinical work quickly led to clinical studies that initially
evaluated OPG but then switched to an antibody to RANKL.
The antibody to RANKL is now named AMG 162 or
denosumab. A phase I clinical study demonstrated efficacy
similar to that with OPG in terms of rapidly reducing
biochemical markers of bone turnover [63]. Clinical studies
conducted to determine whether denosumab can prevent
and treat osteoporosis have reported this agent to be very
effective, and within 12 to 24 months it may be approved for
the treatment of osteoporosis [64]. In addition, rheumatoid
arthritis (RA) patients on chronic stable methotrexate therapy
with prevalent bone erosions were randomly assigned to
treatment with AMG 162 or placebo for 1 year; the group
treated with AMG 162 had significantly less structural
deterioration than in the placebo group [65]. These data
suggest that a medication that is a potent inhibitor of
osteoclast maturation and activity, such as AMG 162, may
have utility in the prevention of generalized and localized bone
loss and structural deterioration in patients with RA.
One other important discovery about RANKL and osteo-
clastogenesis is related to the action of hPTH(1-34).
Treatment of osteopenic animals and osteoporotic women
and men is associated with a rapid increase in new bone
formation, with biochemical markers of bone formation
(P1NP, BSAP, and osteocalcin) increasing from baseline
levels within a few weeks of therapy. This is followed by a
slower increase in levels of bone resorption markers (CTX
and C-telopeptide crosslink of type I collagen [NTX]). At about
6 months of treatment with hPTH(1-34), bone formation and
resorption markers are elevated to around the same level
[66]. The mechanism responsible for the increased bone
resorption with hPTH(1-34) treatment was not immediately
clear. However, when the PTH receptor was located on the
osteoblast, we determined that PTH treatment augmented
the maturation of osteoblasts to make bone, but also
stimulated osteoblasts to produce RANKL that augmented
osteoclastogenesis [67]. The need for osteoclastogenesis it
not completely clear but it may be that the bone resorption
allows osteoblast growth factors stored within the bone
matrix to be released into the bone marrow microenvironment
(insulin-like growth factor-I, fibroblast growth factor-2 and
transforming growth factor-β), and these growth factors may
provide continual stimulation of osteoblast differentiation and
activity [68]. Support for this observation comes from clinical
studies in which the bone anabolic effects of PTH appeared
to be blunted in the lumbar spine when PTH and a potent
anti-resorptive agent were used in combination in both
postmenopausal women and men with osteopenia [69,70].
Osteoimmunology and the involvement of the
Wnt signaling pathway in inflammatory bone
destruction
RA is characterized as an inflammatory arthritis in which joint
inflammation results in bone deterioration. In RA, the pro-
inflammatory cytokine TNF-α is critical in driving inflammatory
disease. TNF is mainly produced by macrophages, fibroblasts
and dendritic cells, and in synovitis associated with RA, and it
is responsible for activating osteoclastogenesis. Bone
formation is affected in RA, and until very recently it was
believed that TNF production reduced osteogenesis in the
presence of the inflammatory arthritis.
Diarra and coworkers utilized a transgenic mouse that over-
expressed TNF-α [71], which exhibits changes in the joints
that are similar to those observed in human RA. It had been
known for a few years that Wnt signaling proteins are
expressed in inflamed rheumatoid joints, and Diarra and
coworkers hypothesized that Wnt activation of osteogenesis
might be inhibited by Wnt antagonists in the inflamed joint.
They focused their work on DKK-1, which had been reported
to be expressed in inflamed erosive joints [72]. The
investigators treated TNF-transgenic mice and two other
mouse arthritis models with an antibody to DKK-1 and TNF,
and demonstrated that these antibodies protected against
bone erosions, thereby preventing structural deterioration.
They also observed that osteophyte formation was more
pronounced in the arthritic mice treated with the anti-DKK-1
antibody, and no effect on inflammation was observed. These
observations led the investigators to conclude that inhibition
of DKK-1 leads to increased osteogenesis and less osteo-
clastogenesis, with the latter being an indirect effect media-
ted by mature osteoblasts producing more OPG and less
RANKL by pre-osteoblasts.
This study by Diarra and coworkers [71] was a landmark study,
because they demonstrated that DKK-1, the Wnt signaling
antagonist, can connect the immune system to bone
metabolism. The paradigm now is that the pro-inflammatory
cytokine TNF-α induces the expression of DKK-1 from
fibroblasts such as synoviocytes and other cells within the
synovium, such that bone formation is inhibited in the presence
of inflammatory arthritis. In addition, by preventing osteoblast
maturation, pre-osteoblasts are able to produce more RANKL;
and with less mature osteoblasts, less OPG is synthesized,
which results in increased osteoclastogenesis [73].
Another group of investigators carried this work further and
collected synovium from patients with RA, and then treated
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synoviocytes (FLSs) gene expression of DKK-1 increased
more than threefold, followed by modest elevations in IL-1
and IL-6 (as measured by quantitative reverse transcription
polymerase chain reaction) [74]. To translate this observation
to RA patients, they collected serum and synovial samples
and they found that DKK-1 was elevated in serum and that
DKK-1 expression was increased in FLS samples. However,
DKK-1 expression was decreased in synovial samples from
osteoarthritis patients [74].
These studies are seminal to our understanding of
inflammatory bone loss and lead us to hypothesize that, with
the TNF-α-induced synovitis that accompanies RA, DKK-1,
IL-1, and IL-6 are produced that are able to inhibit osteo-
genesis and accelerate osteoclastogenesis. When TNF-
transgenic mice were treated with inhibitors of TNF and
DKK-1, these agents prevented nearly all of the structural
deterioration of bone and cartilage that accompanies RA
[72]. In RA patients it is possible that treatment with potent
TNF-blocking agents reduce both the synovitis and the
production of DKK-1, IL-1, and IL-6 by FLSs, thereby
preventing some of the structural deterioration in the joints.
These studies suggest that the Wnt signaling pathway, which
is important in joint development, is also important in
diseases of the joint. Further understanding of the Wnt
signaling pathway in bone metabolism will provide new
opportunities for treatment of RA.
Conclusion
This review highlights the developments in out scientific under-
standing of osteoporosis in the past 10 years. We believe, in
the next 10 years, scientific advances in osteoporosis will
improve both the prevention and treatment of this disease.
Competing interests
The authors declare that they have no competing interests. 
Acknowledgements
This work was supported by NIH grants K24 AR04884, R01
AR043052, and the endowment for aging to Dr Lane.
References
1. Datta HK, Ng WF, Walker JA, Tuck SP, Varanasi SS: The cell
biology of bone metabolism. J Clin Pathol 2008, 61:577-587.
2. Sims NA, Gooi JH: Bone remodeling: multiple cellular interac-
tions required for coupling of bone formation and resorption.
Semin Cell Dev Biol 2008, 19:444-451.
3. Lips P, Courpron P, Meunier PJ: Mean wall thickness of trabec-
ular bone packets in the human iliac crest: changes with age.
Calcif Tissue Res 1978, 26:13-17.
4. Gillespie MT: Impact of cytokines and T lymphocytes upon
osteoclast differentiation and function. Arthritis Res Ther 2007,
9:103.
5. Horowitz MC, Lorenzo JA: B lymphocytes and the skeleton. Ann
N Y Acad Sci 2007, 1117:82-93.
6. Elefteriou F: Regulation of bone remodeling by the central and
peripheral nervous system. Arch Biochem Biophys 2008, 473:
231-236.
7. Shahnazari M, Yao W, Corr M, Lane NE: Targeting the Wnt sig-
naling pathway to augment bone formation. Curr Osteoporos
Rep 2008, 6:142-148.
8. Huang H, He X: Wnt/beta-catenin signaling: new (and old)
players and new insights. Curr Opin Cell Biol 2008, 20:119-
125.
9. Gordon MD, Nusse R: Wnt signaling: multiple pathways, multi-
ple receptors, and multiple transcription factors. J Biol Chem
2006, 281:22429-22433.
10. Vlad A, Rohrs S, Klein-Hitpass L, Muller O: The first five years of
the Wnt targetome. Cell Signal 2008, 20:795-802.
11. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G,
Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R,
Ducy P, Karsenty G: Lrp5 controls bone formation by inhibiting
serotonin synthesis in the duodenum. Cell  2008,  135:825-
837.
12. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato
AM, Wang H, Cundy T, Glorieux FH, Lev D, Zacharin M, Oexle K,
Marcelino J, Suwairi W, Heeger S, Sabatakos G, Apte S, Adkins
WN, Allgrove J, Arslan-Kirchner M, Batch JA, Beighton P, Black
GC, Boles RG, Boon LM, Borrone C, Brunner HG, Carle GF, Dal-
lapiccola B, De Paepe A, et al.: LDL receptor-related protein 5
(LRP5) affects bone accrual and eye development. Cell 2001,
107:513-523.
13. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, Wu
D, Insogna K, Lifton RP: High bone density due to a mutation in
LDL-receptor-related protein 5. N Engl J Med 2002, 346:1513-
1521.
14. Little RD, Carulli JP, Del Mastro RG, Dupuis J, Osborne M, Folz C,
Manning SP, Swain PM, Zhao SC, Eustace B, Lappe MM, Spitzer
L, Zweier S, Braunschweiger K, Benchekroun Y, Hu X, Adair R,
Chee L, FitzGerald MG, Tulig C, Caruso A, Tzellas N, Bawa A,
Franklin B, McGuire S, Nogues X, Gong G, Allen KM, Anisowicz
A, Morales AJ, et al.: A mutation in the LDL receptor-related
protein 5 gene results in the autosomal dominant high-bone-
mass trait. Am J Hum Genet 2002, 70:11-19.
15. Akhter MP, Wells DJ, Short SJ, Cullen DM, Johnson ML, Haynatzki
GR, Babij P, Allen KM, Yaworsky PJ, Bex F, Recker RR: Bone
biomechanical properties in LRP5 mutant mice. Bone 2004,
35:162-169.
16. Babij P, Zhao W, Small C, Kharode Y, Yaworsky PJ, Bouxsein ML,
Reddy PS, Bodine PV, Robinson JA, Bhat B, Marzolf J, Moran RA,
Bex F: High bone mass in mice expressing a mutant LRP5
gene. J Bone Miner Res 2003, 18:960-974.
17. Ferrari SL, Deutsch S, Baudoin C, Cohen-Solal M, Ostertag A,
Antonarakis SE, Rizzoli R, de Vernejoul MC: LRP5 gene polymor-
phisms and idiopathic osteoporosis in men. Bone 2005, 37:
770-775.
18. Semenov MV, He X: LRP5 mutations linked to high bone mass
diseases cause reduced LRP5 binding and inhibition by
SOST. J Biol Chem 2006, 281:38276-38284.
19. Balemans W, Ebeling M, Patel N, Van Hul E, Olson P, Dioszegi M,
Lacza C, Wuyts W, Van Den Ende J, Willems P, Paes-Alves AF,
Hill S, Bueno M, Ramos FJ, Tacconi P, Dikkers FG, Stratakis C,
Lindpaintner K, Vickery B, Foernzler D, Van Hul W: Increased
bone density in sclerosteosis is due to the deficiency of a
novel secreted protein (SOST). Hum Mol Genet 2001, 10:537-
543.
20. Balemans W, Foernzler D, Parsons C, Ebeling M, Thompson A,
Reid DM, Lindpaintner K, Ralston SH, Van Hul W: Lack of asso-
Arthritis Research & Therapy    Vol 11 No 3 Lane and Yao
Page 6 of 8
(page number not for citation purposes)
This article is part of a special collection of reviews, The
Scientific Basis of Rheumatology: A Decade of
Progress, published to mark Arthritis Research &
Therapy’s 10th anniversary.
Other articles in this series can be found at: 
http://arthritis-research.com/sbr
The Scientific Basis 
of Rheumatology: 
A Decade of Progressciation between the SOST gene and bone mineral density in
perimenopausal women: analysis of five polymorphisms.
Bone 2002, 31:515-519.
21. Balemans W, Patel N, Ebeling M, Van Hul E, Wuyts W, Lacza C,
Dioszegi M, Dikkers FG, Hildering P, Willems PJ, Verheij JB, Lind-
paintner K, Vickery B, Foernzler D, Van Hul W: Identification of a
52 kb deletion downstream of the SOST gene in patients with
van Buchem disease. J Med Genet 2002, 39:91-97.
22. Brunkow ME, Gardner JC, Van Ness J, Paeper BW, Kovacevich
BR, Proll S, Skonier JE, Zhao L, Sabo PJ, Fu Y, Alisch RS, Gillett
L, Colbert T, Tacconi P, Galas D, Hamersma H, Beighton P, Mulli-
gan J: Bone dysplasia sclerosteosis results from loss of the
SOST gene product, a novel cystine knot-containing protein.
Am J Hum Genet 2001, 68:577-589.
23. Li J, Sarosi I, Cattley RC, Pretorius J, Asuncion F, Grisanti M,
Morony S, Adamu S, Geng Z, Qiu W, Kostenuik P, Lacey DL,
Simonet WS, Bolon B, Qian X, Shalhoub V, Ominsky MS, Zhu Ke
H, Li X, Richards WG: Dkk1-mediated inhibition of Wnt signal-
ing in bone results in osteopenia. Bone 2006, 39:754-766.
24. Morvan F, Boulukos K, Clément-Lacroix P, Roman Roman S, Suc-
Royer I, Vayssière B, Ammann P, Martin P, Pinho S, Pognonec P,
Mollat P, Niehrs C, Baron R, Rawadi G: Deletion of a single
allele of the Dkk1 gene leads to an increase in bone forma-
tion and bone mass. J Bone Miner Res 2006, 21:934-945.
25. Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy
JD, Jr.: Antibody-based inhibition of DKK1 suppresses tumor-
induced bone resorption and multiple myeloma growth in
vivo. Blood 2007, 109:2106-2111.
26. Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J,
Barlogie B, Shaughnessy JD Jr: Myeloma-derived Dickkopf-1
disrupts Wnt-regulated osteoprotegerin and RANKL produc-
tion by osteoblasts: a potential mechanism underlying osteo-
lytic bone lesions in multiple myeloma. Blood  2008,  112:
196-207.
27. Hall CL, Keller ET: The role of Wnts in bone metastases.
Cancer Metastasis Rev 2006, 25:551-558.
28. Voorzanger-Rousselot N, Goehrig D, Journe F, Doriath V, Body JJ,
Clezardin P, Garnero P: Increased Dickkopf-1 expression in
breast cancer bone metastases. Br J Cancer 2007, 97:964-
970.
29. Hurson CJ, Butler JS, Keating DT, Murray DW, Sadlier DM,
O’Byrne JM, Doran PP: Gene expression analysis in human
osteoblasts exposed to dexamethasone identifies altered
developmental pathways as putative drivers of osteoporosis.
BMC Musculoskelet Disord 2007, 8:12.
30. Yao W, Cheng Z, Busse C, Pham A, Nakamura MC, Lane NE:
Glucocorticoid excess in mice results in early activation of
osteoclastogenesis and adipogenesis and prolonged sup-
pression of osteogenesis: a longitudinal study of gene
expression in bone tissue from glucocorticoid-treated mice.
Arthritis Rheum 2008, 58:1674-1686.
31. Yao W, Cheng Z, Busse C, Pham A, LANE N: Overexpression of
secreted frizzled-related protein 1 inhibits bone formation
and attenuates PTH bone anabolic effects [abstract]. J Bone
Miner Res 2008, 23(suppl 1):S29.
32. Blair H, Sun L, Kohanski RA: Balanced regulation of prolifera-
tion, growth, differentiation, and degradation in skeletal cells.
Ann N Y Acad Sci 2007, 1116:165-173.
33. Takada I, Suzawa M, Matsumoto K, Kato S: Suppression of
PPAR-γ γ transactivation switches cell fate of bone marrow
stem cells from adipocytes into osteoblasts. Ann N Y Acad Sci
2007, 1116:182-195.
34. Almeida M, Han L, Bellido T, Manolagas SC, Kousteni S: Wnt pro-
teins prevent apoptosis of both uncommitted osteoblast
progenitors and differentiated osteoblasts by beta-catenin-
dependent and -independent signaling cascades involving
Src/ERK and phosphatidylinositol 3-kinase/AKT. J Biol Chem
2005, 280:41342-41351.
35. Baron R, Rawadi G: Targeting the Wnt/beta-catenin pathway
to regulate bone formation in the adult skeleton. Endocrinol-
ogy 2007, 148:2635-2643.
36. Baron R, Rawadi G, Roman-Roman S: Wnt signaling: a key reg-
ulator of bone mass. Curr Top Dev Biol 2006, 76:103-127.
37. Holmen SL, Giambernardi TA, Zylstra CR, Buckner-Berghuis BD,
Resau JH, Hess JF, Glatt V, Bouxsein ML, Ai M, Warman ML,
Williams BO: Decreased BMD and limb deformities in mice
carrying mutations in both Lrp5 and Lrp6. J Bone Miner Res
2004, 19:2033-2040.
38. Cheon SS, Cheah AY, Turley S, Nadesan P, Poon R, Clevers H,
Alman BA: beta-Catenin stabilization dysregulates mesenchy-
mal cell proliferation, motility, and invasiveness and causes
aggressive fibromatosis and hyperplastic cutaneous wounds.
Proc Natl Acad Sci USA 2002, 99:6973-6978.
39. Williams LJ, Henry MJ, Berk M, Dodd S, Jacka FN, Kotowicz MA,
Nicholson GC, Pasco JA: Selective serotonin reuptake
inhibitor use and bone mineral density in women with a
history of depression. Int Clin Psychopharmacol 2008, 23:84-
87.
40. Haney EM, Chan BK, Diem SJ, Ensrud KE, Cauley JA, Barrett-
Connor E, Orwoll E, Bliziotes MM: Association of low bone
mineral density with selective serotonin reuptake inhibitor
use by older men. Arch Intern Med 2007, 167:1246-1251.
41. Noble BS: The osteocyte lineage. Arch Biochem Biophys 2008,
473:106-111.
42. Laughlin SB, de Ruyter van Steveninck RR, Anderson JC: The
metabolic cost of neural information. Nat Neurosci 1998, 1:36-
41.
43. Keller H, Kneissel M: SOST is a target gene for PTH in bone.
Bone 2005, 37:148-158.
44. Belanger LF, Narbaitz R: The mecanism of cementing line for-
mation in the bones of cestrum-fed chicks. Rev Can Biol
1978, 37:5-14.
45. Drueke T, Bordier PJ, Man NK, Jungers P, Marie P: Effects of
high dialysate calcium concentration on bone remodelling,
serum biochemistry, and parathyroid hormone in patients
with renal osteodystrophy. Kidney Int 1977, 11:267-274.
46. Wright PH, Jowsey JO, Robb RA: Osteocyte lacunar area in
normal bone, hyperparathyroidism, renal disease, and osteo-
porosis. Surg Forum 1978, 29:558-559.
47. Belanger LF: Osteocytic osteolysis. Calcif Tissue Res 1969, 4:
1-12.
48. Lane NE, Yao W, Balooch M, Nalla RK, Balooch G, Habelitz S,
Kinney JH, Bonewald LF: Glucocorticoid-treated mice have
localized changes in trabecular bone material properties and
osteocyte lacunar size that are not observed in placebo-
treated or estrogen-deficient mice. J Bone Miner Res 2006,
21:466-476.
49. Yao W, Cheng Z, Pham A, Busse C, Zimmermann EA, Ritchie
RO, Lane NE: Glucocorticoid-induced bone loss in mice can
be reversed by the actions of parathyroid hormone and rise-
dronate on different pathways for bone formation and miner-
alization. Arthritis Rheum 2008, 58:3485-3497.
50. Teti A, Zallone A: Do osteocytes contribute to bone mineral
homeostasis? Osteocytic osteolysis revisited. Bone 2009, 44:
11-16.
51. Noble BS, Peet N, Stevens HY, Brabbs A, Mosley JR, Reilly GC,
Reeve J, Skerry TM, Lanyon LE: Mechanical loading: biphasic
osteocyte survival and targeting of osteoclasts for bone
destruction in rat cortical bone. Am J Physiol Cell Physiol
2003, 284:C934-C943.
52. Balemans W, Piters E, Cleiren E, Ai M, Van Wesenbeeck L,
Warman ML, Van Hul W: The binding between sclerostin and
LRP5 is altered by DKK1 and by high-bone mass LRP5 muta-
tions. Calcif Tissue Int 2008, 82:445-453.
53. Bellido T: Downregulation of SOST/sclerostin by PTH: a novel
mechanism of hormonal control of bone formation mediated
by osteocytes. J Musculoskelet Neuronal Interact 2006, 6:358-
359.
54. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D’Agostin D,
Kurahara C, Gao Y, Cao J, Gong J, Asuncion F, Barrero M, Warm-
ington K, Dwyer D, Stolina M, Morony S, Sarosi I, Kostenuik PJ,
Lacey DL, Simonet WS, Ke HZ, Paszty C: Targeted deletion of
the sclerostin gene in mice results in increased bone forma-
tion and bone strength. J Bone Miner Res 2008, 23:860-869.
55. Li X, Ominsky MS, Warmington KS, Morony S, Gong J, Cao J,
Gao Y, Shalhoub V, Tipton B, Haldankar R, Chen Q, Winters A,
Boone T, Geng Z, Niu QT, Ke HZ, Kostenuik PJ, Simonet WS,
Lacey DL, Paszty C: Sclerostin antibody treatment increases
bone formation, bone mass and bone strength in a rat model
of postmenopausal osteoporosis. J Bone Miner Res 2009, 24:
578-588.
56. Padhi D, Stouch B, Jang G, Fang L, Darling M, Glise H, Robinson
M, Harris S, Posvar E: Anti-sclerostin antibody increases
markers of bone formation in healthy postmenopausal
Available online http://arthritis-research.com/content/11/3/228
Page 7 of 8
(page number not for citation purposes)women [abstract]. J Bone Miner Res 2007, 22(suppl 1):S37.
57. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T,
Elliott R, Colombero A, Elliott G, Scully S, Hsu H, Sullivan J,
Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S,
Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell 1998, 93:165-176.
58. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M,
Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E,
Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T:
Osteoclast differentiation factor is a ligand for osteoprote-
gerin/osteoclastogenesis-inhibitory factor and is identical to
TRANCE/RANKL. Proc Natl Acad Sci USA 1998,  95:3597-
3602.
59. Gallagher JC: Advances in bone biology and new treatments
for bone loss. Maturitas 2008, 60:65-69.
60. Simonet WS, Lacey DL, Dunstan CR, Kelley M, Chang MS, Lüthy
R, Nguyen HQ, Wooden S, Bennett L, Boone T, Shimamoto G,
DeRose M, Elliott R, Colombero A, Tan HL, Trail G, Sullivan J,
Davy E, Bucay N, Renshaw-Gegg L, Hughes TM, Hill D, Pattison
W, Campbell P, Sander S, Van G, Tarpley J, Derby P, Lee R,
Boyle WJ: Osteoprotegerin: a novel secreted protein involved
in the regulation of bone density. Cell 1997, 89:309-319.
61. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C,
Scully S, Tan HL, Xu W, Lacey DL, Boyle WJ, Simonet WS:
osteoprotegerin-deficient mice develop early onset osteo-
porosis and arterial calcification. Genes Dev 1998, 12:1260-
1268.
62. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C,
Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W,
Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Pen-
ninger JM: OPGL is a key regulator of osteoclastogenesis,
lymphocyte development and lymph-node organogenesis.
Nature 1999, 397:315-323.
63. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW,
Leese PT, Holmes GB, Dunstan CR, DePaoli AM: A single-dose
placebo-controlled study of AMG 162, a fully human mono-
clonal antibody to RANKL, in postmenopausal women. J Bone
Miner Res 2004, 19:1059-1066.
64. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson
GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut
CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC,
Bekker PJ; AMG 162 Bone Loss Study Group: Denosumab in
postmenopausal women with low bone mineral density. N
Engl J Med 2006, 354:821-831.
65. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van
der Heijde D, Zhou L, Tsuji W, Newmark R: Denosumab treat-
ment effects on structural damage, bone mineral density, and
bone turnover in rheumatoid arthritis: a twelve-month, multi-
center, randomized, double-blind, placebo-controlled, phase II
clinical trial. Arthritis Rheum 2008, 58:1299-1309.
66. Lane NE, Sanchez S, Modin GW, Genant HK, Pierini E, Arnaud
CD:  Parathyroid hormone treatment can reverse corticos-
teroid-induced osteoporosis. Results of a randomized con-
trolled clinical trial. J Clin Invest 1998, 102:1627-1633.
67. Buxton EC, Yao W, Lane NE: Changes in serum receptor acti-
vator of nuclear factor-kappaB ligand, osteoprotegerin, and
interleukin-6 levels in patients with glucocorticoid-induced
osteoporosis treated with human parathyroid hormone (1-34).
J Clin Endocrinol Metab 2004, 89:3332-3336.
68. Hurley M, Yao W, Lane NE: Changes in serum fibroblast
growth factor 2 in patients with glucocorticoid-induced osteo-
porosis treated with human parathyroid hormone (1-34).
Osteoporos Int 2005, 16:2080-2084.
69. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA,
Lang TF, Garnero P, Bouxsein ML, Bilezikian JP, Rosen CJ: The
effects of parathyroid hormone and alendronate alone or in
combination in postmenopausal osteoporosis. N Engl J Med
2003, 349:1207-1215.
70. Finkelstein JS, Hayes A, Hunzelman JL, Wyland JJ, Lee H, Neer
RM: The effects of parathyroid hormone, alendronate, or both
in men with osteoporosis. N Engl J Med 2003, 349:1216-1226.
71. Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D,
Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D,
Landewe R, Lacey D, Richards WG, Schett G: Dickkopf-1 is a
master regulator of joint remodeling. Nat Med 2007, 13:156-
163.
72. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kious-
sis D, Kollias G: Transgenic mice expressing human tumour
necrosis factor: a predictive genetic model of arthritis. EMBO
J 1991, 10:4025-4031.
73. Goldring SR, Goldring MB: Eating bone or adding it: the Wnt
pathway decides. Nat Med 2007, 13:133-134.
74. Corr M: Wnt-beta-catenin signaling in the pathogenesis of
osteoarthritis. Nat Clin Pract Rheumatol 2008, 4:550-556.
Arthritis Research & Therapy    Vol 11 No 3 Lane and Yao
Page 8 of 8
(page number not for citation purposes)